Cardax, Inc. has accepted the request for a leave of absence by Nicholas Mitsakos as the Chairman of the company. Effective August 12, 2016, Mr. Mitsakos will not be the Chairman or member of the board of directors of the company. Mr. Mitsakos has noted that his decision was not related to any disagreement with the company on any matter relating to the company's operations, policies and practices. Effective August 12, 2016, George W. Bickerstaff, III, a current member of the board of directors of the company, was appointed Chairman.
Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.
CARDAX, INC. 
